NMN: Evidenz, Dosierung, Sicherheit & Wechselwirkungen
β-Nicotinamide mononucleotide
This is a supplement your body can turn into a molecule your cells need for energy and repair, which naturally drops as you age. It has decent early evidence in people, but scientists still don't know if raising this molecule actually makes you healthier long-term.
- What it is
- A direct NAD+ precursor. NAD+ declines with age and drives cellular energy and repair.
- Evidence
- Raises blood NAD+; improved walking distance, muscle insulin sensitivity, and cholesterol in separate trials. No lifespan or disease-outcome data.
- Studied dose
- 250–2,000 mg/day orally, over 4 to 10 weeks.
- Safety
- No safety issues reported in published trials at up to 2,000 mg/day. Nothing is known beyond 10 weeks.
Was Studien am Menschen tatsächlich zeigen
Ausschließlich randomisierte, placebokontrollierte Studien am Menschen. Tierdaten erscheinen hier nie — sie können eine Bewertung nicht anheben und werden weiter unten separat vermerkt.
- 01Science2021— Muscle insulin sensitivity
- Design
- Randomized, double-blind, placebo-controlled
- Dosis
- 250 mg/day
- Dauer
- 10 weeks
25 postmenopausal women with prediabetes who were overweight or obese
Insulin-stimulated glucose disposal in muscle rose 25±7% versus no change on placebo. Notably, muscle NAD+ content itself did not change, and body composition, blood pressure, lipids, and grip strength were unaffected. No adverse events were reported.
doi:10.1126/science.abe9985 - 02GeroScience2022— Dose-ranging, NAD+ and physical function
- Design
- Randomized, multicentre, double-blind, placebo-controlled
- Dosis
- 300, 600 or 900 mg/day
- Dauer
- 60 days
80 healthy middle-aged adults
Blood NAD+ rose at every dose. Six-minute walking distance improved versus placebo at all three doses, and self-reported health scores improved. The authors reported efficacy highest at 600 mg/day. No safety issues were found at any dose.
doi:10.1007/s11357-022-00705-1 - 03Journal of Clinical Endocrinology & Metabolism2023— Cardiometabolic markers
- Design
- Randomized, placebo-controlled (2:1)
- Dosis
- 1,000 mg twice daily (a pharmaceutical-grade NMN, MIB-626)
- Dauer
- 28 days
30 overweight or obese adults aged 45 and over
Body weight fell 1.9 kg, LDL cholesterol 18.7 mg/dL, and diastolic blood pressure 7.0 mmHg versus placebo. Insulin sensitivity, intra-abdominal fat, muscle strength and aerobic capacity did not change. Adverse events were similar between groups.
doi:10.1210/clinem/dgad027 - 04Journal of the International Society of Sports Nutrition2021— Aerobic capacity, alongside training
- Design
- Randomized, double-blind, placebo-controlled
- Dosis
- 300, 600 or 1,200 mg/day
- Dauer
- 6 weeks
48 amateur runners in structured training
Oxygen uptake and both ventilatory thresholds improved at 600 and 1,200 mg/day versus placebo. Peak power and VO₂max did not change — and every participant was training 5–6 times a week, so this is not an effect of NMN alone.
doi:10.1186/s12970-021-00442-4
No human trial has measured lifespan, disease outcomes, or anything beyond 10 weeks of dosing. The trials also disagree with each other: NMN improved muscle insulin sensitivity in the Science trial but changed nothing about insulin sensitivity in the JCEM trial. And in the one study that looked, muscle NAD+ content did not rise even though blood NAD+ did — so the mechanism people assume is at work has not actually been shown in muscle.
Grade B — vielversprechend. Multiple randomized human trials show real biomarker and functional effects, but no trial has measured disease outcomes or run longer than 10 weeks. Wie wir Evidenz bewerten.
Nebenwirkungen & Sicherheit
- Reported in trials
- Mild nausea, flushing and gastrointestinal discomfort. Published randomized trials reported NMN as well tolerated, with adverse events similar to placebo.
- Serious events
- None attributed to NMN in the published randomized trials to date.
- The honest caveat
- The longest published trial ran 10 weeks. Long-term safety — the thing that actually matters for a compound you would take for decades — is unknown.
Wechselwirkungen mit Medikamenten
Der Abschnitt, den die meisten Longevity-Seiten auslassen. Wenn Sie verschreibungspflichtige Medikamente nehmen, lesen Sie dies vor allem anderen auf dieser Seite.
NMN improved muscle insulin sensitivity in one randomized trial. A combined effect on glucose control is plausible, so check your readings more closely in the first weeks.
Diastolic blood pressure fell 7 mmHg in one trial. Additive lowering is plausible — recheck home readings during the first week.
LDL cholesterol fell in one trial. Not a safety problem, but it can confound how you read your next lipid panel — tell whoever ordered it.
NAD+ biology cuts both ways in oncology and the human data does not settle it. Do not add NMN during treatment without your oncologist's explicit sign-off.
No trials have been conducted in pregnancy or breastfeeding. Absence of data is not evidence of safety — avoid.
Ist NMN in Ihrem Land legal?
Der Zulassungsstatus wird pro Markt erfasst und zum angegebenen Datum überprüft. Ist eine Substanz nicht zugelassen, verlinkt diese Seite nicht auf Verkäufer.
Widely sold as a dietary supplement. The FDA moved to exclude NMN from that category in 2022 on drug-preclusion grounds, and the position remains unresolved — products stay on sale while it is contested.
Quelle: US Food and Drug Administration
Treated as an unauthorised novel food. It is not legally sold as a food supplement in the UK, and no NMN product has completed novel-food authorisation.
Quelle: UK Food Standards Agency
Same novel-food position as the UK: NMN has no authorisation for sale as a food supplement in the EU.
Quelle: European Commission / EFSA
La France applique le règlement européen sur les nouveaux aliments : le NMN n'est pas autorisé à la vente comme complément alimentaire.
Quelle: European Commission / EFSA
España aplica el reglamento europeo de nuevos alimentos: el NMN no está autorizado para su venta como complemento alimenticio.
Quelle: European Commission / EFSA
Germany applies the EU novel-food rules, so NMN may not be sold as a food supplement. Products reaching German buyers are imported against that position.
Quelle: BVL / European Commission
Sold openly as an anti-aging dietary supplement through MOHAP/DHA-licensed pharmacy chains (Life Pharmacy, BinSina Pharmacy, Al Ain Pharmacy, Aster) and mainstream UAE retailers such as noon.com. We found no public record of MOHAP applying the drug-precedence dispute the US FDA has raised, or of any specific import restriction on NMN — but we also could not query MOHAP's own product-registration database directly, so this reflects observed retail availability through licensed channels rather than a published MOHAP policy statement on NMN specifically.
Quelle: UAE Ministry of Health and Prevention (MOHAP)
Sold as an anti-aging dietary supplement by Saudi retailers including Dr. Nutrition KSA. As with the UAE, we could not query SFDA's own product-registration database directly, so this reflects observed retail availability rather than a published SFDA policy statement on NMN specifically.
Quelle: Saudi Food and Drug Authority (SFDA)
L'Unione Europea non ha ancora autorizzato l'NMN come nuovo alimento (novel food) ai sensi del regolamento (UE) 2015/2283, quindi la vendita come integratore alimentare non è legale in nessuno Stato membro, Italia inclusa. Nonostante ciò, diversi prodotti a base di NMN risultano notificati nel Registro nazionale degli integratori alimentari del Ministero della Salute — una notifica è un'autodichiarazione dell'azienda, verificata solo a posteriori, e non equivale a un giudizio di conformità al regolamento sui novel food. Segnaliamo questo scarto reale tra la norma europea e la prassi di mercato italiana piuttosto che ignorarlo.
Quelle: Commissione europea / EFSA; Ministero della Salute (registro nazionale, non equivale ad autorizzazione novel food)
De Europese Commissie bepaalde in 2022 dat NMN een niet-toegelaten nieuw voedingsmiddel (novel food) is; er loopt inmiddels een EFSA-veiligheidsbeoordeling, maar nog geen goedkeuring. Anders dan in Italië lijkt Nederland dit ook daadwerkelijk te handhaven: de brancheorganisaties IVG en NPN meldden dat de verkoop van NMN-producten niet is toegestaan en dat aanbieders producten van de markt hebben moeten halen. We citeren deze brancheberichten omdat we geen directe NVWA-publicatie over een specifieke handhavingsactie konden vinden.
Quelle: Europese Commissie / EFSA; NVWA (via brancheorganisaties IVG/NPN)
A Anvisa havia proibido o NMN em alimentos pela Resolução-RE nº 1.139/2022. Essa proibição foi revogada pela Resolução-RE nº 3.245, publicada em 14 de agosto de 2026, com base na Instrução Normativa nº 418/2025, que passou a autorizar o NMN em suplementos alimentares como fonte de niacina (vitamina B3) — com um teto de aproximadamente 94,85 mg de NMN por dia e advertência obrigatória no rótulo informando que o produto não deve ser consumido por gestantes, lactantes e crianças. É uma mudança muito recente; ainda não observamos como o mercado brasileiro está se ajustando a ela.
Quelle: Agência Nacional de Vigilância Sanitária (ANVISA)
Dosierung & Einnahmezeitpunkt
600 mg was where efficacy peaked in the only dose-ranging trial. Higher doses have been tested for safety, not for extra benefit.
Matches how the trials dosed it. No published evidence favours evening dosing.
Every positive human trial used ordinary oral dosing. No head-to-head study shows sublingual or liposomal forms beat plain capsules.
Kosten: A dose inside the studied range costs meaningfully more than the low-dose products that dominate the shelf — the Science trial noted that typical commercial capsules contain 50–150 mg, well under what the trials used.
Fragen, die tatsächlich gestellt werden
Is NMN safe for long-term daily use?
Unknown, and that is the honest answer. Trials of up to 10 weeks at doses up to 2,000 mg/day reported no safety issues, but nobody has published multi-year human safety data. For a compound people intend to take for decades, that is a real gap rather than a formality.
What dose of NMN is most effective?
In the only trial that compared doses head to head, blood NAD+ and physical performance responded best at 600 mg/day, with 900 mg offering no clear additional benefit. Doses above that have been tested for safety, not for extra effect.
Does NMN or NR raise NAD+ better?
Both raise NAD+ in humans and no head-to-head trial has crowned a winner. NR has longer-running safety data; NMN has the stronger functional-outcome trials so far. Worth knowing: several randomized trials of NR in middle-aged and older men found no effect on insulin sensitivity, which is where NMN showed its clearest result.
Do sublingual or liposomal NMN products absorb better?
That claim runs ahead of the evidence — every positive human trial used ordinary oral capsules or powder. Choose on third-party testing and price per effective dose rather than on a delivery-format story.
Will NMN make me live longer?
No study has shown that in humans. NMN extends healthspan measures in mice, but the human trials have measured biomarkers and short-term function only. Anyone telling you otherwise is describing rodent data.